Acticor Biotech annonce la fin de son étude clinique de phase I – Biotech finance [FR]

February 2018. Acticor Biotech annonce la fin de son étude clinique de phase I avec son candidat médicament ACT017. Cet essai a permis de valider …

Download full text article (PDF, French)

Read next in 'Media Coverage'

• Novel antiplatelet could circumvent bleeding risk for stroke patients
• Experimental antiplatelet compound for acute stroke shows promise
• New drug to prevent clots clears safety hurdle
• New blood thinner may prevent stroke, without risk for bleeding
• Acticor's blood thinner cuts hemorrhage risk in human study, could offer hope for acute stroke